Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders

Kaczmarek, Radosław; Ekiaby, Magdy El; Hart, Daniel P.; Hermans, Cédric; Makris, Michael; Noone, Declan; O’Mahony, Brian; Page, David; Peyvandi, Flora; Pipe, Steven W.; Sannié, Thomas; Schlenkrich, Uwe; Skinner, Mark W; Srivastava, Alok; Bok, Amanda; Pierce, Glenn F.

doi:10.1111/hae.14271

Cited by 13 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Haemostatic support for patients with rare bleeding disorders should depend on the severity of the disorder and be decided in consultation with their treatment centre. 5 …”

Section: Figurementioning

confidence: 99%

Experience of Covid 19 vaccination in patients with bleeding disorders

2021

View full text Add to dashboard Cite

Coronavirus disease 2019 has resulted in an on-going world-wide pandemic and is associated with substantial morbidity and mortality. Vaccination against SARS-CoV-2 is important to help control the pandemic, and effective vaccines have been rapidly developed and several are now licenced. There are no specific contraindications to COVID-19 vaccination for people with inherited bleeding disorders.The COVID vaccine trials demonstrating efficacy have only been performed using an intramuscular (IM) route of administration. There-

show abstract

“…Haemostatic support for patients with rare bleeding disorders should depend on the severity of the disorder and be decided in consultation with their treatment centre. 5 …”

Section: Figurementioning

confidence: 99%

Experience of Covid 19 vaccination in patients with bleeding disorders

2021

View full text Add to dashboard Cite

show abstract

“…al. (2021) [58]: "The rationale behind vaccination is to provide every vaccinated person with protection against the SARS-CoV-2 virus. This protection is achieved by stimulating the immune system to produce antibodies against the virus and to develop lymphocytes that will retain memory and the ability to fight off the virus for a long time.…”

Section: Considerations In the Design Of Mrna Vaccinesmentioning

confidence: 99%

Innate Immune Suppression by SARS-CoV-2 mRNA Vaccinations: The role of G-quadruplexes, exosomes and microRNAs

Seneff

Nigh

Kyriakopoulos³

et al. 2022

Preprint

View full text Add to dashboard Cite

The mRNA SARS-CoV-2 vaccines were brought to market in response to the widely perceived public health crises of Covid-19. The utilization of mRNA vaccines in the context of infectious disease had no precedent, but desperate times seemed to call for desperate measures. The mRNA vaccines utilize genetically modified mRNA encoding spike proteins. These alterations hide the mRNA from cellular defenses, promote a longer biological half-life for the proteins, and provoke higher overall spike protein production. However, both experimental and observational evidence reveals a very different immune response to the vaccines compared to the response to infection with SARS-CoV-2. As we will show, the genetic modifications introduced by the vaccine are likely the source of these differential responses. In this paper, we present the evidence that vaccination, unlike natural infection, induces a profound impairment in type I interferon signaling, which has diverse adverse consequences to human health. We explain the mechanism by which immune cells release into the circulation large quantities of exosomes containing spike protein along with critical microRNAs that induce a signaling response in recipient cells at distant sites. We also identify potential profound disturbances in regulatory control of protein synthesis and cancer surveillance. These disturbances are shown to have a potentially direct causal link to neurodegenerative disease, myocarditis, immune thrombocytopenia, Bell’s palsy, liver disease, impaired adaptive immunity, increased tumorigenesis, and DNA damage. We show evidence from adverse event reports in the VAERS database supporting our hypothesis. We believe a comprehensive risk/benefit assessment of the mRNA vaccines excludes them as positive contributors to public health, even in the context of the Covid-19 pandemic.

show abstract

“…Patients with hemophilia or other bleeding disorders are not at an increased risk of COVID-19 infection, when compared to the general population. [33] Patients with such disorders should be vaccinated with SARS-CoV-2 vaccine, similar to the current guidelines for the general population. Till date, all types of SARS-CoV-2 vaccines available are to be administered through the intramuscular route.…”

Section: Hemophilia and Bleeding Disordersmentioning

confidence: 99%

“…Following the injection, pressure should be applied for at least 10 min at the site of injection. [33] As per Srivastava et al, an ice pack may be applied at the site 5 min before injection, to reduce chances of a hematoma. [34] In case of severe hemophilia or Type III von Willebrand disease, the vaccine shot should be administered after a prophylactic dose of FVIII or FIX and if factor level >10%, often hemostatic precautions were unnecessary.…”

Section: Hemophilia and Bleeding Disordersmentioning

confidence: 99%

“…[34] In case of severe hemophilia or Type III von Willebrand disease, the vaccine shot should be administered after a prophylactic dose of FVIII or FIX and if factor level >10%, often hemostatic precautions were unnecessary. [33] Patients on the newer drug emicizumab may be vaccinated at any time, irrespective of the ongoing drug. [35] Immune thrombocytopenia (ITP) ITP does not increase chances of getting the COVID-19 infection, however, like any other viral infection, COVID-19 often leads to a rapid fall in the platelet count.…”

Section: Hemophilia and Bleeding Disordersmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination for the novel coronavirus disease in hematological disorders

Dolai

Sen

2021

JHAS

View full text Add to dashboard Cite

The coronavirus disease-19 (COVID-19) caused by the SARS-CoV-2 virus, is now an ongoing pandemic. First detected in December 2019 at Wuhan, China, this disease has now spread to all parts of the world. COVID-19 may affect anyone, without regard for age, sex, or underlying disease condition. Patients with benign or malignant diseases when affected, usually have a more severe outcome than people without comorbidities. Increasing one’s immunity by vaccination against COVID-19 will help to improve the disease outcomes of COVID-19 in patients who already have some underlying disease. The live-attenuated or killed and recombinant viral protein vaccines currently available can elicit both humoral and cellular immunities. However, in immunocompromised patients (either due to the disease pathology or treatment-related immunosuppression), immune response may not be as effective as expected. Depending on the underlying disease pathogenesis, the patient may not be able to mount an adequate immune response post-vaccination. However, in view of the severe risks posed by COVID-19 disease, vaccination is of utmost importance. This review aims at understanding the importance of SARS-CoV-2 vaccination in patients with hematological disorders, and also aims to understand the side effects which arise post-SARS-CoV-2 vaccination. We have tried to ascertain the best way to vaccinate patients with hematological disorders.

show abstract

Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders

Cited by 13 publications

References 14 publications

Experience of Covid 19 vaccination in patients with bleeding disorders

Experience of Covid 19 vaccination in patients with bleeding disorders

Innate Immune Suppression by SARS-CoV-2 mRNA Vaccinations: The role of G-quadruplexes, exosomes and microRNAs

Vaccination for the novel coronavirus disease in hematological disorders

Contact Info

Product

Resources

About